HB163 - AN ACT relating to blood donation.

14 Co-Sponsors

Amend KRS 214.450 to define "COVID-19 vaccine" or "mRNA vaccine"; amend KRS 214.452 to require blood establishments to test for COVID-19 antibodies, evidence of lipid nanoparticles, and spike protein; require the administrator of any blood establishment to inquire on the donor history questionnaire whether a donor has received a COVID-19 vaccine or mRNA vaccine; require a donor to provide the name of the manufacturer of the COVID-19 vaccine the donor received; establish deferral periods for donors who have received a live attenuated COVID-19 vaccine or for donors who do not know the manufacturer of the COVID-19 vaccine the donor received, and establish deferral periods for donors who have received a diagnosis of COVID-19 or are displaying symptoms of COVID-19; amend KRS 214.458 to require blood establishments to include on the label for blood collected the laboratory test results for COVID-19.